ADMA Biologics, Inc (NASDAQ:ADMA) Projects Continued Margin Expansion Amid Legal Headwinds

Operational performance shows strong margin expansion and cash generation, while recent legal filings create event-driven volatility. Near-term price action should reflect that split between fundamentals and headline risk.

Recent News

April 29, 2026 — ADMA announced a May 6, 2026 conference call to report first-quarter 2026 financial results.

May 6, 2026 — ADMA reported Q1 2026 results: $114.5 million revenue (flat YoY), ASCENIV revenue +27.7% YoY, adjusted net income $40.7 million (+22% YoY), and adjusted EBITDA $59.7 million (+24% YoY); the company updated its FY 2026 outlook and withdrew long-term guidance.

June 16–26, 2026 — Multiple law firms announced securities class-action investigations and filings related to ADMA, with notices and filing deadlines published in mid–late June.

Technical Analysis

Directional indicators show DI+ at 21.39 with a decreasing trend (bearish) while DI- sits at 19.82 and is increasing (bearish); ADX at 14.49 indicates no established trend. Those readings signal weakening bullish pressure without a clear directional trend, raising near-term volatility against the company’s operational strength.

MACD registers at approximately -0.00 with a decreasing trend and the signal line at 0.03; MACD negative and declining denotes bearish momentum and the indicator remains below its signal line, implying limited immediate upward momentum.

MRO at -7.25 indicates the price sits below the model target and therefore carries potential to adjust upward if momentum returns; that potential coexists with the current bearish momentum readings.

RSI at 48.29 with a peak-and-reversal indicates recent loss of upside momentum but stays near neutral, supporting a sideways-to-range market profile rather than trending breakout.

Price at $8.38 trades below the 20-day average ($8.90) and well below the 200-day average ($13.55), and it sits slightly below the 1× lower Bollinger level ($8.61), reflecting short-term weakness with a modest oversold signature. Volume runs below the 10-, 50- and 200-day averages, implying lower trading participation and muted conviction in any directional move.

 


Fundamental Analysis

Revenue totaled $114,493,000 in Q1 2026, essentially flat YoY, while YoY revenue growth reads +6.59% and QoQ revenue declined by 5.82%. Product-level mix drove ASCENIV growth of 27.7% YoY against a 54.0% YoY decline in BIVIGAM revenue, indicating concentration of growth in ASCENIV.

Margins expanded materially: gross margin at 70.53% and EBIT margin at 51.73%. The EBIT margin sits above the industry peer range high of 25.24% (industry peer mean -1.15%; industry peer median 0.23%), reflecting outsized profitability on current revenue. YoY EBIT margin improved by 67.64% (expressed as 0.67644 in the data) and QoQ moved higher by 13.87%.

Cash and liquidity present a strong profile: cash and short-term investments $138,153,000; operating cash flow $52,105,000; free cash flow $55,653,000; current ratio 6.95 and quick ratio 3.93. Interest coverage at 28.20 and net debt of $58,712,000 yield manageable leverage with debt-to-EBITDA near 3.35.

Earnings details show diluted EPS actual $0.17 versus estimate $0.20 (EPS surprise ratio -15%), forward EPS $0.264 and forward PE ~58.00; trailing PE stands near 74.24. Free cash flow yield registers roughly 1.90% (0.01898). The current valuation as determined by WMDST: over-valued, driven by high multiples (PE and EV/EBITDA) despite healthy cash generation and margin performance.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-03-31
REPORT DATE: 2026-05-06
NEXT REPORT DATE: 2026-08-05
CASH FLOW  Begin Period Cash Flow 87.6 M
 Operating Cash Flow 52.1 M
 Capital Expenditures -2.60 M
 Change In Working Capital 9.2 M
 Dividends Paid
 Cash Flow Delta 50.5 M
 End Period Cash Flow 138.2 M
 
INCOME STATEMENT REVENUE
 Total Revenue 114.5 M
 Forward Revenue 38.7 M
COSTS
 Cost Of Revenue 33.7 M
 Depreciation 1.8 M
 Depreciation and Amortization 1.8 M
 Research and Development 2.6 M
 Total Operating Expenses 64.2 M
PROFITABILITY
 Gross Profit 80.8 M
 EBITDA 61.1 M
 EBIT 59.2 M
 Operating Income 50.3 M
 Interest Income 1.1 M
 Interest Expense 2.1 M
 Net Interest Income -1.01 M
 Income Before Tax 57.1 M
 Tax Provision 11.8 M
 Tax Rate 20.654 %
 Net Income 45.3 M
 Net Income From Continuing Operations 45.3 M
EARNINGS
 EPS Estimate 0.20
 EPS Actual 0.17
 EPS Difference -0.03
 EPS Surprise -15.0 %
 Forward EPS 0.26
 
BALANCE SHEET ASSETS
 Total Assets 665.2 M
 Intangible Assets 4.2 M
 Net Tangible Assets 386.2 M
 Total Current Assets 511.2 M
 Cash and Short-Term Investments 138.2 M
 Cash 138.2 M
 Net Receivables 135.9 M
 Inventory 222.1 M
 Long-Term Investments 8.5 M
LIABILITIES
 Accounts Payable 20.5 M
 Short-Term Debt 3.3 M
 Total Current Liabilities 73.5 M
 Net Debt 58.7 M
 Total Debt 204.4 M
 Total Liabilities 274.9 M
EQUITY
 Total Equity 390.3 M
 Retained Earnings -116.33 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 1.68
 Shares Outstanding 232.289 M
 Revenue Per-Share 0.49
VALUATION
 Market Capitalization 2.9 B
 Enterprise Value 3.0 B
 Enterprise Multiple 49.095
Enterprise Multiple QoQ -20.986 %
Enterprise Multiple YoY -61.434 %
Enterprise Multiple IPRWA high: 75.51
ADMA: 49.095
median: 18.371
mean: 7.011
low: -128.217
 EV/R 26.185
CAPITAL STRUCTURE
 Asset To Equity 1.704
 Asset To Liability 2.42
 Debt To Capital 0.344
 Debt To Assets 0.307
Debt To Assets QoQ 140.127 %
Debt To Assets YoY 91.303 %
Debt To Assets IPRWA high: 1.112
ADMA: 0.307
mean: 0.167
median: 0.031
low: 0.0
 Debt To Equity 0.524
Debt To Equity QoQ 212.906 %
Debt To Equity YoY 138.437 %
Debt To Equity IPRWA high: 1.864
ADMA: 0.524
mean: 0.193
median: 0.051
low: -1.172
PRICE-BASED VALUATION
 Price To Book (P/B) 7.511
Price To Book QoQ -11.762 %
Price To Book YoY -40.951 %
Price To Book IPRWA high: 20.93
mean: 7.542
ADMA: 7.511
median: 5.469
low: -11.267
 Price To Earnings (P/E) 74.242
Price To Earnings QoQ -4.376 %
Price To Earnings YoY -58.989 %
Price To Earnings IPRWA ADMA: 74.242
high: 73.877
mean: -2.619
median: -14.81
low: -121.28
 PE/G Ratio -3.267
 Price To Sales (P/S) 25.606
Price To Sales QoQ -12.296 %
Price To Sales YoY -38.111 %
Price To Sales IPRWA high: 864.732
mean: 64.688
median: 30.918
ADMA: 25.606
low: 0.192
FORWARD MULTIPLES
Forward P/E 58.004
Forward PE/G -2.552
Forward P/S 75.66
EFFICIENCY OPERATIONAL
 Operating Leverage 0.356
ASSET & SALES
 Asset Turnover Ratio 0.178
Asset Turnover Ratio QoQ -23.882 %
Asset Turnover Ratio YoY -22.713 %
Asset Turnover Ratio IPRWA high: 0.403
ADMA: 0.178
mean: 0.102
median: 0.094
low: 0.0
 Receivables Turnover 0.778
Receivables Turnover Ratio QoQ -17.222 %
Receivables Turnover Ratio YoY -49.367 %
Receivables Turnover Ratio IPRWA high: 6.246
mean: 1.268
median: 1.226
ADMA: 0.778
low: 0.013
 Inventory Turnover 0.157
Inventory Turnover Ratio QoQ -36.957 %
Inventory Turnover Ratio YoY -49.799 %
Inventory Turnover Ratio IPRWA high: 2.566
mean: 0.502
median: 0.358
ADMA: 0.157
low: 0.003
 Days Sales Outstanding (DSO) 117.274
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 466.637
Cash Conversion Cycle Days QoQ 24.528 %
Cash Conversion Cycle Days YoY 48.997 %
Cash Conversion Cycle Days IPRWA high: 1575.417
ADMA: 466.637
mean: 227.347
median: 208.031
low: -1586.264
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.262
 CapEx To Revenue -0.023
 CapEx To Depreciation -1.455
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 583.9 M
 Net Invested Capital 587.2 M
 Invested Capital 587.2 M
 Net Tangible Assets 386.2 M
 Net Working Capital 437.6 M
LIQUIDITY
 Cash Ratio 1.879
 Current Ratio 6.951
Current Ratio QoQ 3.614 %
Current Ratio YoY 5.697 %
Current Ratio IPRWA high: 32.587
ADMA: 6.951
mean: 3.943
median: 2.409
low: 0.016
 Quick Ratio 3.931
Quick Ratio QoQ 5.116 %
Quick Ratio YoY 17.071 %
Quick Ratio IPRWA high: 9.985
ADMA: 3.931
mean: 2.764
median: 2.568
low: 0.054
COVERAGE & LEVERAGE
 Debt To EBITDA 3.347
 Cost Of Debt 1.172 %
 Interest Coverage Ratio 28.203
Interest Coverage Ratio QoQ -27.463 %
Interest Coverage Ratio YoY 57.238 %
Interest Coverage Ratio IPRWA high: 604.866
ADMA: 28.203
median: -14.877
mean: -77.342
low: -1643.72
 Operating Cash Flow Ratio 0.709
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 39.005
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 6.559 %
 Revenue Growth -17.727 %
Revenue Growth QoQ -581.712 %
Revenue Growth YoY 658.537 %
Revenue Growth IPRWA high: 269.985 %
median: -7.18 %
mean: -10.086 %
ADMA: -17.727 %
low: -242.388 %
 Earnings Growth -22.727 %
Earnings Growth QoQ -148.7 %
Earnings Growth YoY 6.057 %
Earnings Growth IPRWA high: 215.789 %
median: -5.479 %
mean: -13.519 %
ADMA: -22.727 %
low: -250.0 %
MARGINS
 Gross Margin 70.528 %
Gross Margin QoQ 10.507 %
Gross Margin YoY 32.524 %
Gross Margin IPRWA high: 100.0 %
median: 81.912 %
mean: 77.45 %
ADMA: 70.528 %
low: -98.223 %
 EBIT Margin 51.73 %
EBIT Margin QoQ 13.87 %
EBIT Margin YoY 67.644 %
EBIT Margin IPRWA high: 2524.194 %
ADMA: 51.73 %
median: 23.412 %
mean: -114.803 %
low: -7259.515 %
 Return On Sales (ROS) 43.928 %
Return On Sales QoQ -2.581 %
Return On Sales YoY 42.36 %
Return On Sales IPRWA high: 100.302 %
ADMA: 43.928 %
median: 20.658 %
mean: -114.779 %
low: -7394.476 %
CASH FLOW
 Free Cash Flow (FCF) 55.7 M
 Free Cash Flow Yield 1.898 %
Free Cash Flow Yield QoQ 124.35 %
Free Cash Flow Yield YoY -469.261 %
Free Cash Flow Yield IPRWA high: 11.709 %
ADMA: 1.898 %
median: 0.11 %
mean: -0.531 %
low: -48.369 %
 Free Cash Growth 61.956 %
Free Cash Growth QoQ -101.879 %
Free Cash Growth YoY -140.923 %
Free Cash Growth IPRWA high: 253.163 %
ADMA: 61.956 %
mean: 4.181 %
median: -16.303 %
low: -249.577 %
 Free Cash To Net Income 1.228
 Cash Flow Margin 45.509 %
 Cash Flow To Earnings 1.15
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 7.031 %
Return On Assets QoQ -15.074 %
Return On Assets YoY 30.566 %
Return On Assets IPRWA high: 38.074 %
ADMA: 7.031 %
median: -8.264 %
mean: -13.794 %
low: -67.817 %
 Return On Capital Employed (ROCE) 10.011 %
 Return On Equity (ROE) 0.116
Return On Equity QoQ 12.257 %
Return On Equity YoY 61.18 %
Return On Equity IPRWA high: 0.797
ADMA: 0.116
median: -0.115
mean: -0.345
low: -1.265
 DuPont ROE 10.449 %
 Return On Invested Capital (ROIC) 8.003 %
Return On Invested Capital QoQ -13.237 %
Return On Invested Capital YoY 25.262 %
Return On Invested Capital IPRWA high: 41.877 %
ADMA: 8.003 %
median: 2.185 %
mean: 0.223 %
low: -51.333 %

Six-Week Outlook

Expect range-bound trading with heightened event risk over the next six weeks. Technicals point to no dominant trend and bearish short-term momentum, while MRO and the below-Bollinger price level imply limited upside potential if buying interest returns. Strong margins, cash, and cash-flow metrics provide a fundamental support level, but active legal filings and related notices create headline risk that can amplify volatility. Key near-term catalysts include follow-up disclosures and legal developments; volatility should cluster around those items and the company’s next scheduled report on August 5, 2026.

About ADMA Biologics, Inc.

ADMA Biologics, Inc. (NASDAQ:ADMA) is a cutting-edge biopharmaceutical company dedicated to the innovation, production, and marketing of specialized plasma-derived biologics. With a focus on addressing immune deficiencies and infectious diseases, ADMA Biologics plays a crucial role in enhancing patient care both domestically and internationally. The company’s flagship products include BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies specifically formulated to treat primary humoral immunodeficiency (PI). Additionally, ADMA offers Nabi-HB, a vital treatment for individuals with acute exposure to Hepatitis B. ADMA Biologics is not only committed to its current product line but is also actively developing a robust pipeline of new plasma-derived therapies aimed at preventing and treating infections such as those caused by S. pneumonia. To ensure a consistent supply of high-quality plasma, the company operates its own plasma collection centers, which are integral to its manufacturing process. Established in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics distributes its products through a comprehensive network of independent distributors, drug wholesalers, specialty pharmacies, and alternate site providers. The company continues to make significant contributions to the biopharmaceutical industry, advancing healthcare solutions for those in need.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.